Elaine Shum, MD, discusses emerging targeted therapies in EGFR-mutant non–small cell lung cancer.
Elaine Shum, MD, an assistant professor in the Department of Medicine at NYU Grossman School of Medicine, discusses emerging targeted therapies in EGFR-mutant non–small cell lung cancer (NSCLC).
A growing area of research is aimed at understanding resistance mechanisms that develop following progression on osimertinib (Tagrisso) in patients with EGFR-mutant NSCLC, explains Shum. Although these efforts are largely ongoing, the field hopes to establish a standard of care for patients.
For example, trials are under way evaluating various combinations of MET inhibitors plus osimertinib to try to overcome these resistance mechanisms, Shum says.
Additionally, the investigational agent JNJ-6372 is being evaluated in patients with metastatic NSCLC who harbor EGFR exon 20 insertion mutations, continues Shum.
Other research efforts seek to understand why patients may develop MET amplifications and C797S resistance mutations after osimertinib, Shum concludes.